10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2022 | |||
CONSOLIDATED STATEMENTS OF EARNINGS | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 14, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Total Revenues | $ 46,159 | 46,385 | 42,518 |
| Cost of products sold | 10,137 [1] | 9,940 | 11,773 |
| Marketing, selling and administrative | 7,814 | 7,690 | 7,661 |
| Research and development | 9,509 | 10,195 | 10,048 |
| Acquired IPRD | 815 | 1,159 | 12,533 |
| Amortization of acquired intangible assets | 9,595 | 10,023 | 9,688 |
| Other (income)/expense, net | 576 | (720) | (2,314) |
| Total Expenses | 38,446 | 38,287 | 49,389 |
| Earnings/(Loss) Before Income Taxes | 7,713 | 8,098 | (6,871) |
| Provision for Income Taxes | 1,368 | 1,084 | 2,124 |
| Net Earnings/(Loss) | 6,345 | 7,014 | (8,995) |
| Noncontrolling Interest | 18 | 20 | 20 |
| Net Earnings(Loss) Attributable to BMS | 6,327 | 6,994 | (9,015) |
| Earnings per common share attributable to BMS, basic (in usd per share) | 2.97 | 3.15 | (3.99) |
| Earnings per common share attributable to BMS, diluted (in usd per share) | 2.95 | 3.12 | (3.99) |
| Product and Service | |||
| Net product sales | |||
| Total Revenues | 44,671 | 45,055 | 41,321 |
| Alliance and other revenues | |||
| Total Revenues | 1,488 | 1,330 | 1,197 |
| [1] Excludes amortization of acquired intangible assets. | |||
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2022 | |||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS) | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 14, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Net Earnings/(Loss) | $ 6,345 | 7,014 | (8,995) |
| Other Comprehensive Income/(Loss), net of taxes and reclassifications to earnings: | |||
| Derivatives qualifying as cash flow hedges | 54 | 415 | (256) |
| Pension and postretirement benefits | 145 | 206 | (75) |
| Marketable debt securities | (2) | (9) | 5 |
| Foreign currency translation | (210) | (41) | 7 |
| Total Other Comprehensive Income/(Loss) | (13) | 571 | (319) |
| Comprehensive Income/(Loss) | 6,332 | 7,585 | (9,314) |
| Comprehensive Income Attributable to Noncontrolling Interest | 18 | 20 | 20 |
| Comprehensive Income/(Loss) Attributable to BMS | 6,314 | 7,565 | (9,334) |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
BRISTOL MYERS SQUIBB CO | |||
Ticker: BMY Fiscal Year: 2022 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2022 10-K (Filed: Feb 14, 2023) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
| Cash Flows From Operating Activities: | |||
| Net Earnings/(Loss) | $ 6,345 | 7,014 | (8,995) |
| Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities: | |||
| Depreciation and amortization, net | 10,276 | 10,686 | 10,380 |
| Deferred income taxes | (2,738) | (1,393) | 983 |
| Stock-based compensation | 457 | 583 | 779 |
| Impairment charges | 179 | 1,207 | 1,203 |
| Divestiture gains and royalties | (1,063) | (684) | (699) |
| Acquired IPRD | 815 | 1,159 | 12,533 |
| Equity investment losses/(gains), net | 801 | (745) | (1,228) |
| Contingent consideration fair value adjustments | (9) | (542) | (1,757) |
| Other adjustments | 232 | 183 | (134) |
| Changes in operating assets and liabilities: | |||
| Receivables | (663) | (1,054) | (646) |
| Inventories | (69) | 13 | 2,672 |
| Accounts payable | 109 | 245 | 188 |
| Rebates and discounts | 427 | 863 | 1,189 |
| Income taxes payable | (1,423) | (1,063) | (2,305) |
| Other | (610) | (265) | (111) |
| Net Cash Provided by Operating Activities | 13,066 | 16,207 | 14,052 |
| Cash Flows From Investing Activities: | |||
| Sale and maturities of marketable debt securities | 6,411 | 4,196 | 6,280 |
| Purchase of marketable debt securities | (3,592) | (5,478) | (4,172) |
| Proceeds from sales of equity investment securities | 218 | 2,579 | 129 |
| Capital expenditures | (1,118) | (973) | (753) |
| Divestiture and other proceeds | 1,305 | 748 | 741 |
| Acquisition and other payments, net of cash acquired | (4,286) | (1,610) | (13,084) |
| Net Cash Used in Investing Activities | (1,062) | (538) | (10,859) |
| Cash Flows From Financing Activities: | |||
| Short-term debt obligations, net | 194 | (160) | (267) |
| Issuance of long-term debt | 5,926 | 0 | 6,945 |
| Repayment of long-term debt | (11,431) | (6,022) | (2,750) |
| Repurchase of common stock | (8,001) | (6,287) | (1,546) |
| Dividends | (4,634) | (4,396) | (4,075) |
| Stock option proceeds and other, net | 984 | 641 | 542 |
| Net Cash Used in Financing Activities | (16,962) | (16,224) | (1,151) |
| Effect of Exchange Rates on Cash, Cash Equivalents and Restricted Cash | (33) | (102) | 111 |
| (Decrease)/Increase in Cash, Cash Equivalents and Restricted Cash | (4,991) | (657) | 2,153 |
| Cash, Cash Equivalents and Restricted Cash at Beginning of Year | 14,316 | 14,973 | |
| Cash, Cash Equivalents and Restricted Cash at End of Year | 9,325 | 14,316 | 14,973 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
BRISTOL MYERS SQUIBB CO | ||
Ticker: BMY Fiscal Year: 2022 | ||
CONSOLIDATED BALANCE SHEETS | ||
Period Ending Dec 31, 2022 10-K (Filed: Feb 14, 2023) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2022 | Dec 31, 2021 | |
| ASSETS | ||
| Current Assets: | ||
| Cash and cash equivalents | $ 9,123 | 13,979 |
| Marketable debt securities | 130 | 2,987 |
| Receivables | 9,886 | 9,369 |
| Inventories | 2,339 | 2,095 |
| Other current assets | 5,795 | 4,832 |
| Total Current Assets | 27,273 | 33,262 |
| Property, plant and equipment | 6,255 | 6,049 |
| Goodwill | 21,149 | 20,502 |
| Other intangible assets | 35,859 | 42,527 |
| Deferred income taxes | 1,344 | 1,439 |
| Other non-current assets | 4,940 | 5,535 |
| Total Assets | 96,820 | 109,314 |
| LIABILITIES | ||
| Current Liabilities: | ||
| Short-term debt obligations | 4,264 | 4,948 |
| Accounts payable | 3,040 | 2,949 |
| Other current liabilities | 14,586 | 13,971 |
| Total Current Liabilities | 21,890 | 21,868 |
| Deferred income taxes | 2,166 | 4,501 |
| Long-term debt | 35,056 | 39,605 |
| Other non-current liabilities | 6,590 | 7,334 |
| Total Liabilities | 65,702 | 73,308 |
| Commitments and contingencies | ||
| EQUITY | ||
| Bristol-Myers Squibb Company Shareholders Equity: | ||
| Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,991 in 2022 and 3,484 in 2021, liquidation value of $50 per share | 0 | 0 |
| Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2022 and 2021 | 292 | 292 |
| Capital in excess of par value of stock | 45,165 | 44,361 |
| Accumulated other comprehensive loss | (1,281) | (1,268) |
| Retained earnings | 25,503 | 23,820 |
| Less cost of treasury stock 825 million common shares in 2022 and 747 million common shares in 2021 | (38,618) | (31,259) |
| Total Bristol-Myers Squibb Company Shareholders Equity | 31,061 | 35,946 |
| Noncontrolling interest | 57 | 60 |
| Total Equity | 31,118 | 36,006 |
| Total Liabilities and Equity | 96,820 | 109,314 |
| External Links | |
| BRISTOL MYERS SQUIBB CO (BMY) Fiscal Year 2022 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |